1.17 Improvements means any invention made by MedImmune or a Joint Invention derived from the use of Potelligent Cells or Potelligent Cell related BioWa Know How, and to the extent it relates specifically to Potelligent Cells or Potelligent Cell related BioWa Know How. For the purpose of this definition only, Improvements does not include inventions that relate to antibody structure, antibody formulation, methods of using antibodies, processes for manufacturing antibodies (other than inventions directed to the generation of Potelligent Cells) and/or inventions incorporating any of the following: (i) antibody expression constructs, (ii) methods of transfecting cells and selecting transfected cells, (iii) cell culture media, (iv) cell culture conditions, and/or (v) other methods and compositions for enhancing the expression and recovery of recombinant proteins from cultured cells.
1.18 IND means mean an Investigational New Drug Application, as defined in the US Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder, or the equivalent thereto as specified in any succeeding legislation, or its non-US equivalent for initiating clinical trials in the US or any non-US country.
1.19 IP means intellectual property.
1.20 IP Claim means a claim or assertion of IP infringement made against BioWa or its Affiliates or licensees by any Third Party in the Territory.
1.21 Joint Invention has the meaning set forth in Section 6.1.1.
1.22 Joint Patent Rights means patents and patent applications claiming a Joint Invention, which remains jointly owned following the operation of Sections 6.1.2 and 6.1.3.
1.23 Know-How means any proprietary technical or other information, whether patentable or not and whether in written or verbal form, including without limitation technology, experience, formulae, concepts, discoveries, trade secrets, inventions, modifications, improvements, data (including without limitation all chemical, preclinical, pharmacological, clinical, toxicologic, analytical, quality control and pharmacologic data), results, designs, ideas, analyses, methods, techniques, assays, research plans, procedures, tests, processes (including manufacturing processes, specifications and techniques), laboratory records, reports, summaries, and information contained in submissions to, and information from, regulatory authorities which are proprietary to a Party.
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.